Titre :

Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination

Auteur(s) :

Alidjinou, Enagnon Kazali [Auteur]
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Demaret, Julie [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Corroyer-Simovic, Bénédicte [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Vuotto, Fanny [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Miczek, Sophie [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Labreuche, Julien [Auteur]
Service de Biostatistiques [CHRU Lille]
Goffard, Anne [Auteur]
Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 [CIIL]
Trauet, Jacques [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lupau, Daniela [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Dendooven, Arnaud [Auteur]
Institute for Translational Research in Inflammation - U 1286 [INFINITE]
Huvent-Grelle, Dominique [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Podvin, Juliette [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Dreuil, Daniel [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Faure, Karine [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Deplanque, Dominique [Auteur]
Centre d'Investigation Clinique - Innovation Technologique de Lille - CIC 1403 - CIC 9301 [CIC Lille]
Bocket, Laurence [Auteur]
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Duhamel, Alain [Auteur]
Evaluation des technologies de santé et des pratiques médicales - ULR 2694 [METRICS]
Sobaszek, Annie [Auteur]
Impact de l'environnement chimique sur la santé humaine - ULR 4483 [IMPECS]
Hober, Didier [Auteur]
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Hisbergues, Michael [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Puisieux, Francois [Auteur]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Autran, Brigitte [Auteur]
Centre d'Immunologie et des Maladies Infectieuses [CIMI]
Yazdanpanah, Yazdan [Auteur]
AP-HP - Hôpital Bichat - Claude Bernard [Paris]
Infection, Anti-microbiens, Modélisation, Evolution [IAME (UMR_S_1137 / U1137)]
Labalette, Myriam [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]
Lefevre, Guillaume [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]

Titre de la revue :

Clinical Microbiology and Infection

Pagination :

P258.e1-258.e4

Éditeur :

Elsevier for the European Society of Clinical Microbiology and Infectious Diseases

Date de publication :

2022-10-15

ISSN :

1198-743X

Mot(s)-clé(s) en anglais :

COVID-19
Neutralizing antibodies
Omicron
T cells

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

ObjectivesWe investigated serum neutralizing activity against BA.1 and BA.2 Omicron sublineages and T cell response before and 3 months after administration of the booster vaccine in healthcare workers (HCWs).MethodsHCWs ...
Lire la suite >ObjectivesWe investigated serum neutralizing activity against BA.1 and BA.2 Omicron sublineages and T cell response before and 3 months after administration of the booster vaccine in healthcare workers (HCWs).MethodsHCWs aged 18–65 years who were vaccinated and received booster doses of the BNT162b2 vaccine were included. Anti–SARS coronavirus 2 IgG levels and cellular response (through interferon γ ELISpot assay) were evaluated in all participants, and neutralizing antibodies against Delta, BA.1, and BA.2 were evaluated in participants with at least one follow-up visit 1 or 3 months after the administration of the booster dose.ResultsAmong 118 HCWs who received the booster dose, 102 and 84 participants attended the 1-month and 3-month visits, respectively. Before the booster vaccine dose, a low serum neutralizing activity against Delta, BA.1, and BA.2 was detectable in only 39/102 (38.2%), 8/102 (7.8%), and 12/102 (11.8%) participants, respectively. At 3 months, neutralizing antibodies against Delta, BA.1, and BA.2 were detected in 84/84 (100%), 79/84 (94%), and 77/84 (92%) participants, respectively. Geometric mean titres of neutralizing antibodies against BA.1 and BA.2 were 2.2-fold and 2.8-fold reduced compared with those for Delta. From 1 to 3 months after the administration of the booster dose, participants with a recent history of SARS coronavirus 2 infection (n = 21/84) had persistent levels of S1 reactive specific T cells and neutralizing antibodies against Delta and BA.2 and 2.2-fold increase in neutralizing antibodies against BA.1 (p 0.014). Conversely, neutralizing antibody titres against Delta (2.5-fold decrease, p < 0.0001), BA.1 (1.5-fold, p 0.02), and BA.2 (2-fold, p < 0.0001) declined from 1 to 3 months after the administration of the booster dose in individuals without any recent infection.DiscussionThe booster vaccine dose provided significant and similar response against BA.1 and BA.2 Omicron sublineages; however, the immune response declined in the absence of recent infection.Lire moins >

Langue :

Anglais

Vulgarisation :

Non

Collections :

• Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017

Source :

Harvested from HAL